Bicycle Therapeutics (BCYC) to Release Earnings on Thursday

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 1st. Analysts expect Bicycle Therapeutics to post earnings of ($0.86) per share and revenue of $8.67 million for the quarter.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.75) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.10. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The business had revenue of $3.70 million for the quarter, compared to analysts' expectations of $5.47 million. During the same quarter last year, the firm earned ($1.16) EPS. The firm's revenue for the quarter was down 30.2% compared to the same quarter last year. On average, analysts expect Bicycle Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Bicycle Therapeutics Stock Down 0.8 %

Bicycle Therapeutics stock traded down $0.07 during midday trading on Tuesday, reaching $8.33. The stock had a trading volume of 20,050 shares, compared to its average volume of 395,576. The firm's 50-day moving average price is $8.92 and its 200 day moving average price is $14.81. Bicycle Therapeutics has a 12 month low of $6.10 and a 12 month high of $28.67. The firm has a market capitalization of $576.45 million, a PE ratio of -2.53 and a beta of 1.40.

Wall Street Analyst Weigh In

BCYC has been the subject of a number of research reports. HC Wainwright reaffirmed a "buy" rating and issued a $33.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, February 26th. Needham & Company LLC reissued a "buy" rating and set a $30.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, April 9th. Finally, Stephens restated an "equal weight" rating and issued a $15.00 price objective on shares of Bicycle Therapeutics in a report on Wednesday, January 22nd. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $29.14.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.